Paul Melmeyer Rare Disease Incentives 101

Incentivizing Innovation for

Paul Melmeyer

There is generally a greater willingness to pay among just about everybody for

#SaveOrphanDrugs -- Lastest Update from Paul Melmeyer

Rare Disease

Paul Melmeyer

Therapies for

Rare Disease

Dr Lucy McKay explains to you why M4RD made

March 21, 2016 - Future Directions for Undiagnosed

Have you ever wondered how pharmaceutical companies are encouraged to develop therapies for

From all of us at NORD, we'd like to say a huge thank you to our advocates who took the time over the past few months to ...

Day 1: General Session, Value, Pricing & Costs of

In the

Paul Melmeyer

Interview with NORD.

Hartmann Wellhoefer, MD, head of medical affairs at Shire talks about the company's commitment to providing patients with

Millan Patel, MD of B.C. Children's & Women's Hospital and co-founder of the

Does Canada need an Orphan Drug Policy to incentivize drug development and submissions? What was the rationale for Orphan ...

Rare Disease